TIG2; RARRES2; Tazarotene-Induced Gene 2; Retinoic Acid Receptor Responder 2,Tazarotene Induced; RAR-responsive protein TIG2
NR1-H3; LXR-A; LXRA; RLD-1; Nuclear Receptor Subfamily 1,Group H,Member 3; Oxysterols receptor LXR-alpha
HBGF4; HST; HSTF1; KFGF; K-FGF; Heparin Secretory Transforming Protein 1; Kaposi Sarcoma Oncogene; Transforming Protein KS3; FGF-Related Oncogene
CG1; KNT; Kinesin Receptor; CG-1 antigen; Kinesin receptor
TAG; Triacylglycerol; Triacylglyceride
HBGF4; HST; HSTF1; KFGF; K-FGF; Heparin Secretory Transforming Protein 1; Kaposi Sarcoma Oncogene; Transforming Protein KS3; FGF-Related Oncogene
KLC; KNS2; KNS2A; hKLC1S; hKLC1N; hKLC1P; hKLC1G; hKLC1R; hKLC1J; hKLC1B; Kinesin 2
KNS1; UKHC; KINH; Conventional kinesin heavy chain; Ubiquitous kinesin heavy chain; Kinesin-1 heavy chain
HBGF3; INT2; Heparin-binding growth factor 3; Murine Mammary Tumor Virus Integration Site(v-int-2)Oncogene Homolog; INT-2 Proto-Oncogene Protein; Proto-oncogene Int-2
NKHC; MY050; SPG10; Spastic Paraplegia 10(Autosomal Dominant); Kinesin heavy chain neuron-specific 1; Neuronal kinesin heavy chain
HBGF3; INT2; Heparin-binding growth factor 3; Murine Mammary Tumor Virus Integration Site(v-int-2)Oncogene Homolog; INT-2 Proto-Oncogene Protein; Proto-oncogene Int-2
G3PD; GAPD; Peptidyl-cysteine S-nitrosylase GAPDH